Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Verve Therapeutics Inc.

    NASDAQ: VERV · Real-Time Price · USD
    6.19
    0.46 (8.03%)
    At close: Jun 06, 2025, 3:59 PM
    6.19
    0.00%
    After-hours: Jun 06, 2025, 05:59 PM EDT

    Verve Therapeutics Statistics

    Share Statistics

    Verve Therapeutics has 89.14M shares outstanding. The number of shares has increased by 5.75% in one year.

    Shares Outstanding

    n/a
    		 89.14M

    Shares Change (YoY)

    n/a
    		 5.75%

    Shares Change (QoQ)

    n/a
    		 4.88%

    Owned by Institutions (%)

    n/a
    		 93.39%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 211

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 18.41M, so 20.65% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 18.41M

    Short % of Shares Out

    n/a
    		 20.65%

    Short % of Float

    n/a
    		 24.46%

    Short Ratio (days to cover)

    n/a
    		 6.2

    Valuation Ratios

    The PE ratio is -2.4 and the forward PE ratio is -2.13. Verve Therapeutics's PEG ratio is 0.1.

    PE Ratio

    n/a
    		 -2.4

    Forward PE

    n/a
    		 -2.13

    PS Ratio

    n/a
    		 14.78

    Forward PS

    n/a
    		 21

    PB Ratio

    n/a
    		 0.97

    P/FCF Ratio

    n/a
    		 -2.96

    PEG Ratio

    n/a
    		 0.1
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Verve Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 12.65, with a Debt / Equity ratio of 0.14.

    Current Ratio

    n/a
    		 12.65

    Quick Ratio

    n/a
    		 12.65

    Debt / Equity

    n/a
    		 0.14

    Debt / EBITDA

    n/a
    		 -0.32

    Debt / FCF

    n/a
    		 -0.43

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $118,000

    Profits Per Employee

    n/a
    		 $-725,215.33

    Employee Count

    n/a
    		 274

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 349K

    Effective Tax Rate

    n/a
    		 -0.18%

    Stock Price Statistics

    The stock price has increased by 18.81% in the last 52 weeks. The beta is 1.68, so Verve Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.68

    52-Week Price Change

    n/a
    		 18.81%

    50-Day Moving Average

    n/a
    		 4.6

    200-Day Moving Average

    n/a
    		 5.68

    Relative Strength Index (RSI)

    n/a
    		 70.23

    Average Volume (20 Days)

    n/a
    		 3,351,969

    Income Statement

    In the last 12 months, Verve Therapeutics had revenue of 32.33M and earned -198.71M in profits. Earnings per share was -2.36.

    Revenue

    n/a
    		 32.33M

    Gross Profit

    n/a
    		 32.33M

    Operating Income

    n/a
    		 -228.66M

    Net Income

    n/a
    		 -198.71M

    EBITDA

    n/a
    		 -221.91M

    EBIT

    n/a
    		 -228.66M

    Earnings Per Share (EPS)

    n/a
    		 -2.36
    Full Income Statement

    Balance Sheet

    The company has 172.56M in cash and 69.98M in debt, giving a net cash position of 102.58M.

    Cash & Cash Equivalents

    n/a
    		 172.56M

    Total Debt

    n/a
    		 69.98M

    Net Cash

    n/a
    		 102.58M

    Retained Earnings

    n/a
    		 -743.01M

    Total Assets

    n/a
    		 614.16M

    Working Capital

    n/a
    		 459.67M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -157.69M and capital expenditures -3.74M, giving a free cash flow of -161.43M.

    Operating Cash Flow

    n/a
    		 -157.69M

    Capital Expenditures

    n/a
    		 -3.74M

    Free Cash Flow

    n/a
    		 -161.43M

    FCF Per Share

    n/a
    		 -1.91
    Full Cash Flow Statement

    Margins

    Gross margin is 79.11%, with operating and profit margins of -707.23% and -614.59%.

    Gross Margin

    n/a
    		 79.11%

    Operating Margin

    n/a
    		 -707.23%

    Pretax Margin

    n/a
    		 -613.51%

    Profit Margin

    n/a
    		 -614.59%

    EBITDA Margin

    n/a
    		 -686.34%

    EBIT Margin

    n/a
    		 -707.23%

    FCF Margin

    n/a
    		 -499.28%

    Dividends & Yields

    VERV does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for VERV is $24, which is 287.7% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $24

    Price Target Difference

    n/a
    		 287.7%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.14

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist